AR094262A1 - Compuestos antivirales para el tratamiento de la hepatitis c - Google Patents

Compuestos antivirales para el tratamiento de la hepatitis c

Info

Publication number
AR094262A1
AR094262A1 ARP130105004A ARP130105004A AR094262A1 AR 094262 A1 AR094262 A1 AR 094262A1 AR P130105004 A ARP130105004 A AR P130105004A AR P130105004 A ARP130105004 A AR P130105004A AR 094262 A1 AR094262 A1 AR 094262A1
Authority
AR
Argentina
Prior art keywords
formulas
compounds
formula
optionally substituted
group
Prior art date
Application number
ARP130105004A
Other languages
English (en)
Inventor
M Bacon Elizabeth
O Link John
A Trejo Martin Teresa
J Cottel Jeromy
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50974893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR094262(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR094262A1 publication Critical patent/AR094262A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

La divulgación se refiere a compuestos antivirales, composiciones que contienen dichos compuestos y métodos terapéuticos que incluyen la administración de dichos compuestos. Reivindicación 1: Un compuesto de fórmula (1): E¹ᵃ-V¹ᵃ-C(=O)-P¹ᵃ-W¹ᵃ-P¹ᵇ-C(=O)-V¹ᵇ-E¹ᵇ (1) donde: W¹ᵃ es un compuesto de fórmula (2) y W¹ᵃ está opcionalmente sustituido por uno o más halo, alquilo, haloalquilo, arilo opcionalmente sustituido, heterociclo opcionalmente sustituido o ciano; Y⁵ es -O-CH₂-, -CH₂-O-, -O-C(=O)-, o -C(=O)-O-; X⁵ es -CH₂-CH₂-, o-CH=CH-; P¹ᵃ y P¹ᵇ son cada uno independientemente seleccionados del grupo de fórmulas (3); V¹ᵃ y V¹ᵇ son cada uno independientemente seleccionados del grupo de fórmulas (4), siempre que al menos uno de V¹ᵃ y V¹ᵇ sea del grupo de fórmulas (5); E¹ᵃ y E¹ᵇ son cada uno independientemente -N(H)(alcoxicarbonilo), -N(H)(cicloalquilcarbonilo), o -N(H)(cicloalquiloxicarbonilo); o E¹ᵃ-V¹ᵃ juntos son R⁹ᵃ; E¹ᵇ-V¹ᵇ juntos son R⁹ᵇ; R⁹ᵃ y R⁹ᵇ son cada uno independientemente un resto de fórmula (6) ó (7); o una sal farmacéuticamente aceptable o profármaco de esta.
ARP130105004A 2012-12-21 2013-12-20 Compuestos antivirales para el tratamiento de la hepatitis c AR094262A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745452P 2012-12-21 2012-12-21
US13/830,346 US9233974B2 (en) 2012-12-21 2013-03-14 Antiviral compounds

Publications (1)

Publication Number Publication Date
AR094262A1 true AR094262A1 (es) 2015-07-22

Family

ID=50974893

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130105004A AR094262A1 (es) 2012-12-21 2013-12-20 Compuestos antivirales para el tratamiento de la hepatitis c

Country Status (28)

Country Link
US (5) US9233974B2 (es)
EP (3) EP3404030A1 (es)
JP (1) JP6333849B2 (es)
KR (2) KR102164390B1 (es)
CN (2) CN107011350A (es)
AP (1) AP2015008511A0 (es)
AR (1) AR094262A1 (es)
AU (1) AU2013361195B2 (es)
BR (1) BR112015014333A8 (es)
CA (1) CA2893963C (es)
CL (1) CL2015001702A1 (es)
CR (1) CR20150370A (es)
EA (2) EA201790781A3 (es)
ES (1) ES2626392T3 (es)
HK (3) HK1214594A1 (es)
IL (1) IL239496A0 (es)
MA (1) MA38261A1 (es)
MD (1) MD20150062A2 (es)
MX (1) MX2015007888A (es)
PE (1) PE20151423A1 (es)
PH (1) PH12015501354A1 (es)
PL (1) PL2935279T3 (es)
PT (1) PT2935279T (es)
SG (1) SG11201504746PA (es)
SI (1) SI2935279T1 (es)
TW (2) TW201835087A (es)
UY (1) UY35241A (es)
WO (1) WO2014100500A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI640526B (zh) 2010-11-17 2018-11-11 基利法瑪席特有限責任公司 抗病毒化合物
ME02196B (me) 2011-11-16 2016-02-20 Gilead Pharmasset Llc Kondenzovani imidazolilimidazoli kao antiviralna jedinjenja
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
KR102168621B1 (ko) 2012-12-21 2020-10-22 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
US9398640B2 (en) 2012-12-21 2016-07-19 Halliburton Energy Services, Inc. Digital multi-use thermo-cup
JP6467404B2 (ja) 2013-03-14 2019-02-13 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７モジュレーター
US9604982B2 (en) 2013-03-14 2017-03-28 Janssen Pharmaceutica Nv P2X7 modulators
MX363936B (es) 2013-03-14 2019-04-09 Boehringer Ingelheim Int (bencil-ciano-metil)-amidas del acido 2-aza-biciclo[2.2.1]heptano- 3-carboxilico sustituidas como inhibidores de catepsina c.
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
EP3021845A1 (en) 2013-07-17 2016-05-25 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
MA40225B1 (fr) 2014-06-17 2019-05-31 Pfizer Composés dihydroisoquinolinone substitués
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
NZ728684A (en) 2014-09-12 2022-09-30 Boehringer Ingelheim Int Spirocyclic inhibitors of cathepsin c
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
CN110372559A (zh) * 2014-12-29 2019-10-25 重庆博腾制药科技股份有限公司 一种(4S)-N-Boc-4--甲氧基甲基-L-脯氨酸的合成方法
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN105732765B (zh) * 2016-02-01 2019-07-26 杭州科巢生物科技有限公司 丙肝药物维帕他韦的新合成方法
CN106916134B (zh) * 2016-04-14 2020-04-17 苏州楚凯药业有限公司 一种10,11-二氢-5H-苯并[d]萘并[2,3-b]吡喃酮衍生物的制备方法
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP3454856A4 (en) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
JP6770098B2 (ja) 2016-05-27 2020-10-14 ギリアード サイエンシーズ， インコーポレイテッド Ｎｓ５ａ、ｎｓ５ｂまたはｎｓ３阻害剤を使用する、ｂ型肝炎ウイルス感染症を処置するための方法
CN106831737B (zh) * 2017-02-27 2020-03-17 上海众强药业有限公司 维帕他韦及其衍生物的制备
CN111194217B (zh) * 2017-09-21 2024-01-12 里伯赛恩斯有限责任公司 作为hcv rna复制抑制剂的4’-氟-2’-甲基取代的核苷衍生物
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN113164458A (zh) 2018-09-28 2021-07-23 詹森药业有限公司 单酰基甘油脂肪酶调节剂
EP3856178A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
EP4038070A1 (en) 2019-09-30 2022-08-10 Janssen Pharmaceutica NV Radiolabelled mgl pet ligands
EP4126860A1 (en) 2020-03-26 2023-02-08 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
CN117460734A (zh) * 2021-05-21 2024-01-26 吉利德科学公司 作为寨卡病毒抑制剂的五环衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DE69129650T2 (de) 1990-09-14 1999-03-25 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
ATE516293T1 (de) 2004-07-16 2011-07-15 Gilead Sciences Inc Antivirale verbindungen
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20120040977A1 (en) * 2009-02-23 2012-02-16 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
TWI640526B (zh) * 2010-11-17 2018-11-11 基利法瑪席特有限責任公司 抗病毒化合物
US8552047B2 (en) * 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae

Also Published As

Publication number Publication date
ES2626392T3 (es) 2017-07-24
SI2935279T1 (sl) 2017-06-30
EP2935279B1 (en) 2017-03-15
CR20150370A (es) 2015-08-14
EP3404030A1 (en) 2018-11-21
TWI613202B (zh) 2018-02-01
US20170369502A1 (en) 2017-12-28
CA2893963A1 (en) 2014-06-26
SG11201504746PA (en) 2015-07-30
WO2014100500A1 (en) 2014-06-26
CN104918943A (zh) 2015-09-16
BR112015014333A2 (pt) 2017-07-11
CL2015001702A1 (es) 2015-08-07
TW201835087A (zh) 2018-10-01
PE20151423A1 (es) 2015-10-17
PL2935279T3 (pl) 2017-08-31
PH12015501354A1 (en) 2015-09-07
EA201790781A2 (ru) 2017-08-31
CN104918943B (zh) 2017-04-05
UY35241A (es) 2014-07-31
CN107011350A (zh) 2017-08-04
US20160362416A1 (en) 2016-12-15
JP2016503800A (ja) 2016-02-08
HK1214594A1 (zh) 2016-07-29
HK1216177A1 (zh) 2016-10-21
EP3239152A1 (en) 2017-11-01
JP6333849B2 (ja) 2018-05-30
BR112015014333A8 (pt) 2019-10-15
AU2013361195A1 (en) 2015-06-11
TW201441229A (zh) 2014-11-01
AU2013361195B2 (en) 2018-05-17
US20160083395A1 (en) 2016-03-24
MX2015007888A (es) 2015-09-29
CA2893963C (en) 2021-09-07
AP2015008511A0 (en) 2015-06-30
KR102164390B1 (ko) 2020-10-12
US20180244684A1 (en) 2018-08-30
PT2935279T (pt) 2017-06-02
MA38261A1 (fr) 2017-06-30
EA027828B1 (ru) 2017-09-29
MD20150062A2 (ro) 2015-12-31
EP2935279A1 (en) 2015-10-28
EA201590868A1 (ru) 2015-11-30
KR20150100728A (ko) 2015-09-02
HK1245263A1 (zh) 2018-08-24
US20140178336A1 (en) 2014-06-26
EA201790781A3 (ru) 2017-11-30
US9233974B2 (en) 2016-01-12
KR20200118903A (ko) 2020-10-16
IL239496A0 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
AR094262A1 (es) Compuestos antivirales para el tratamiento de la hepatitis c
DOP2014000121A (es) Derivados de betulina
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
UY32490A (es) Inhibidores de beta-secretasa
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
CO6561783A2 (es) Inhibidores del virus flaviviridae
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
PE20160658A1 (es) Nucleosidos sustituidos, nucleotidos y analogos de los mismos
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
EA030189B8 (ru) Аналоги 2'-хлоронуклеозидов для инфекции вгс
ES2722048T3 (es) Compuestos de triazolopirimidina y usos de los mismos
AR103222A1 (es) Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
AR094314A1 (es) Inhibidores de fosfatidilinositol 3-cinasa
CO6140024A2 (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cancer
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
UY35263A (es) Compuestos terapéuticos
MD20180040A2 (ro) Inhibitori ai virusului hepatic C
PE20142148A1 (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
CU24039B1 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
ECSP13012812A (es) Formulaciones inmunosupresoras

Legal Events

Date Code Title Description
FB Suspension of granting procedure